Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients With Moderate-to-severe Atopic Dermatitis

Next Previous
Trial Profile

A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients With Moderate-to-severe Atopic Dermatitis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APG 777 (Primary) ; Lebrikizumab
  • Indications Atopic dermatitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms APEX
  • Sponsors Apogee Therapeutics

Most Recent Events

  • 06 Jul 2025 According to an Apogee Therapeutics media release, company announced it will report Part A 16-week data from the Phase 2 APEX trial of APG777 on Monday, July 7, 2025. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.
  • 03 Feb 2025 According to an Apogee Therapeutics media release, the company announced the first patient has been dosed in the Part B portion of the Phase 2 APEX clinical trial of APG777 in patients with moderate-to-severe AD, as well as enrollment completion in the Part A portion of the trial, Part A 16-week proof-of-concept data anticipated in mid-2025 and maintenance data in the first half of 2026 as well as Part B 16-week data in the second half of 2026.
  • 07 Jan 2025 Planned number of patients changed from 471 to 391.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top